Physician profile
Seth Frampton
NPI 1396154050
$9,946.97
in general payments reported to CMS, 2019-2025
25 companies · $2,320 in 2025
The $2,320 reported for 2025 was more than what 94% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,626 · 2022: $1,559 · 2023: $1,752 · 2024: $2,691 · 2025: $2,320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,708 · Education: $54.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,708.07 |
| Education | $54.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,578.30 | 2021-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Lundbeck LLC | $1,058.34 | 2021-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Abbvie INC. | $1,045.27 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $742.51 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $725.94 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $691.42 | 2021-2025 | Invega, Spravato, Invega Sustenna |
| Alkermes, INC. | $625.30 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Ironshore Pharmaceuticals INC. | $516.15 | 2022-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $514.90 | 2021-2025 | Qelbree, Qelbree |
| E.R. Squibb & Sons, L.L.C. | $444.51 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $438.23 | 2021-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $326.67 | 2021-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $292.79 | 2021-2025 | Trintellix |
| Axsome Therapeutics, INC. | $269.29 | 2022-2025 | Auvelity |
| Corium, LLC | $170.60 | 2021-2024 | Azstarys |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $146.17 | 2022-2024 | Loreev Xr, Sertraline Hcl |
| Collegium Pharmaceutical, INC. | $119.95 | 2025 | Jornay Pm |
| Tris Pharma INC | $68.90 | 2022-2024 | Dyanavel Xr |
| Eisai INC. | $47.55 | 2021 | |
| Noven Therapeutics, LLC | $31.13 | 2021 | |
| Jazz Pharmaceuticals INC. | $29.42 | 2021 | |
| Indivior INC. | $17.21 | 2023 | Perseris |
| Avanir Pharmaceuticals, INC. | $16.97 | 2022 | |
| Aytu Biopharma, INC. | $16.33 | 2021 | |
| Neuronetics, INC. | $13.12 | 2023 | Neurostar Tms Therapy System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Frampton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.